The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Brand Drugs Market Research Report 2024
Synopsis
A medication (also referred to as medicine, pharmaceutical drug, or simply drug) is a drug used to diagnose, cure, treat, or prevent disease. Drug therapy (pharmacotherapy) is an important part of the medical field and relies on the science of pharmacology for continual advancement and on pharmacy for appropriate management.
The global Brand Drugs market was valued at US$ 1071000 million in 2023 and is anticipated to reach US$ 1507000 million by 2030, witnessing a CAGR of 5.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Brand Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Brand Drugs.
Report Scope
The Brand Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Brand Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Brand Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Roche
Sanofi
Johnson & Johnson
Merck & Co. (MSD)
Novartis
AbbVie
Gilead Sciences
GlaxoSmithKline (GSK)
Amgen
AstraZeneca
Bristol-Myers Squibb
Eli Lilly
Teva
Bayer
Novo Nordisk
AbbVie
Takeda
Boehringer Ingelheim
Takeda
Segment by Type
Biopharmaceutical
Chemistry Medicine
Segment by Application
Hospital
Clinic
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Brand Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
A medication (also referred to as medicine, pharmaceutical drug, or simply drug) is a drug used to diagnose, cure, treat, or prevent disease. Drug therapy (pharmacotherapy) is an important part of the medical field and relies on the science of pharmacology for continual advancement and on pharmacy for appropriate management.
The global Brand Drugs market was valued at US$ 1071000 million in 2023 and is anticipated to reach US$ 1507000 million by 2030, witnessing a CAGR of 5.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Brand Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Brand Drugs.
Report Scope
The Brand Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Brand Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Brand Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Roche
Sanofi
Johnson & Johnson
Merck & Co. (MSD)
Novartis
AbbVie
Gilead Sciences
GlaxoSmithKline (GSK)
Amgen
AstraZeneca
Bristol-Myers Squibb
Eli Lilly
Teva
Bayer
Novo Nordisk
AbbVie
Takeda
Boehringer Ingelheim
Takeda
Segment by Type
Biopharmaceutical
Chemistry Medicine
Segment by Application
Hospital
Clinic
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Brand Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Brand Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Biopharmaceutical
1.2.3 Chemistry Medicine
1.3 Market by Application
1.3.1 Global Brand Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Brand Drugs Market Perspective (2019-2030)
2.2 Brand Drugs Growth Trends by Region
2.2.1 Global Brand Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Brand Drugs Historic Market Size by Region (2019-2024)
2.2.3 Brand Drugs Forecasted Market Size by Region (2025-2030)
2.3 Brand Drugs Market Dynamics
2.3.1 Brand Drugs Industry Trends
2.3.2 Brand Drugs Market Drivers
2.3.3 Brand Drugs Market Challenges
2.3.4 Brand Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Brand Drugs Players by Revenue
3.1.1 Global Top Brand Drugs Players by Revenue (2019-2024)
3.1.2 Global Brand Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Brand Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Brand Drugs Revenue
3.4 Global Brand Drugs Market Concentration Ratio
3.4.1 Global Brand Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Brand Drugs Revenue in 2023
3.5 Brand Drugs Key Players Head office and Area Served
3.6 Key Players Brand Drugs Product Solution and Service
3.7 Date of Enter into Brand Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Brand Drugs Breakdown Data by Type
4.1 Global Brand Drugs Historic Market Size by Type (2019-2024)
4.2 Global Brand Drugs Forecasted Market Size by Type (2025-2030)
5 Brand Drugs Breakdown Data by Application
5.1 Global Brand Drugs Historic Market Size by Application (2019-2024)
5.2 Global Brand Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Brand Drugs Market Size (2019-2030)
6.2 North America Brand Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Brand Drugs Market Size by Country (2019-2024)
6.4 North America Brand Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Brand Drugs Market Size (2019-2030)
7.2 Europe Brand Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Brand Drugs Market Size by Country (2019-2024)
7.4 Europe Brand Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Brand Drugs Market Size (2019-2030)
8.2 Asia-Pacific Brand Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Brand Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Brand Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Brand Drugs Market Size (2019-2030)
9.2 Latin America Brand Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Brand Drugs Market Size by Country (2019-2024)
9.4 Latin America Brand Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Brand Drugs Market Size (2019-2030)
10.2 Middle East & Africa Brand Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Brand Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Brand Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Brand Drugs Introduction
11.1.4 Pfizer Revenue in Brand Drugs Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche Brand Drugs Introduction
11.2.4 Roche Revenue in Brand Drugs Business (2019-2024)
11.2.5 Roche Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Detail
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Brand Drugs Introduction
11.3.4 Sanofi Revenue in Brand Drugs Business (2019-2024)
11.3.5 Sanofi Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Detail
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Brand Drugs Introduction
11.4.4 Johnson & Johnson Revenue in Brand Drugs Business (2019-2024)
11.4.5 Johnson & Johnson Recent Development
11.5 Merck & Co. (MSD)
11.5.1 Merck & Co. (MSD) Company Detail
11.5.2 Merck & Co. (MSD) Business Overview
11.5.3 Merck & Co. (MSD) Brand Drugs Introduction
11.5.4 Merck & Co. (MSD) Revenue in Brand Drugs Business (2019-2024)
11.5.5 Merck & Co. (MSD) Recent Development
11.6 Novartis
11.6.1 Novartis Company Detail
11.6.2 Novartis Business Overview
11.6.3 Novartis Brand Drugs Introduction
11.6.4 Novartis Revenue in Brand Drugs Business (2019-2024)
11.6.5 Novartis Recent Development
11.7 AbbVie
11.7.1 AbbVie Company Detail
11.7.2 AbbVie Business Overview
11.7.3 AbbVie Brand Drugs Introduction
11.7.4 AbbVie Revenue in Brand Drugs Business (2019-2024)
11.7.5 AbbVie Recent Development
11.8 Gilead Sciences
11.8.1 Gilead Sciences Company Detail
11.8.2 Gilead Sciences Business Overview
11.8.3 Gilead Sciences Brand Drugs Introduction
11.8.4 Gilead Sciences Revenue in Brand Drugs Business (2019-2024)
11.8.5 Gilead Sciences Recent Development
11.9 GlaxoSmithKline (GSK)
11.9.1 GlaxoSmithKline (GSK) Company Detail
11.9.2 GlaxoSmithKline (GSK) Business Overview
11.9.3 GlaxoSmithKline (GSK) Brand Drugs Introduction
11.9.4 GlaxoSmithKline (GSK) Revenue in Brand Drugs Business (2019-2024)
11.9.5 GlaxoSmithKline (GSK) Recent Development
11.10 Amgen
11.10.1 Amgen Company Detail
11.10.2 Amgen Business Overview
11.10.3 Amgen Brand Drugs Introduction
11.10.4 Amgen Revenue in Brand Drugs Business (2019-2024)
11.10.5 Amgen Recent Development
11.11 AstraZeneca
11.11.1 AstraZeneca Company Detail
11.11.2 AstraZeneca Business Overview
11.11.3 AstraZeneca Brand Drugs Introduction
11.11.4 AstraZeneca Revenue in Brand Drugs Business (2019-2024)
11.11.5 AstraZeneca Recent Development
11.12 Bristol-Myers Squibb
11.12.1 Bristol-Myers Squibb Company Detail
11.12.2 Bristol-Myers Squibb Business Overview
11.12.3 Bristol-Myers Squibb Brand Drugs Introduction
11.12.4 Bristol-Myers Squibb Revenue in Brand Drugs Business (2019-2024)
11.12.5 Bristol-Myers Squibb Recent Development
11.13 Eli Lilly
11.13.1 Eli Lilly Company Detail
11.13.2 Eli Lilly Business Overview
11.13.3 Eli Lilly Brand Drugs Introduction
11.13.4 Eli Lilly Revenue in Brand Drugs Business (2019-2024)
11.13.5 Eli Lilly Recent Development
11.14 Teva
11.14.1 Teva Company Detail
11.14.2 Teva Business Overview
11.14.3 Teva Brand Drugs Introduction
11.14.4 Teva Revenue in Brand Drugs Business (2019-2024)
11.14.5 Teva Recent Development
11.15 Bayer
11.15.1 Bayer Company Detail
11.15.2 Bayer Business Overview
11.15.3 Bayer Brand Drugs Introduction
11.15.4 Bayer Revenue in Brand Drugs Business (2019-2024)
11.15.5 Bayer Recent Development
11.16 Novo Nordisk
11.16.1 Novo Nordisk Company Detail
11.16.2 Novo Nordisk Business Overview
11.16.3 Novo Nordisk Brand Drugs Introduction
11.16.4 Novo Nordisk Revenue in Brand Drugs Business (2019-2024)
11.16.5 Novo Nordisk Recent Development
11.17 AbbVie
11.17.1 AbbVie Company Detail
11.17.2 AbbVie Business Overview
11.17.3 AbbVie Brand Drugs Introduction
11.17.4 AbbVie Revenue in Brand Drugs Business (2019-2024)
11.17.5 AbbVie Recent Development
11.18 Takeda
11.18.1 Takeda Company Detail
11.18.2 Takeda Business Overview
11.18.3 Takeda Brand Drugs Introduction
11.18.4 Takeda Revenue in Brand Drugs Business (2019-2024)
11.18.5 Takeda Recent Development
11.19 Boehringer Ingelheim
11.19.1 Boehringer Ingelheim Company Detail
11.19.2 Boehringer Ingelheim Business Overview
11.19.3 Boehringer Ingelheim Brand Drugs Introduction
11.19.4 Boehringer Ingelheim Revenue in Brand Drugs Business (2019-2024)
11.19.5 Boehringer Ingelheim Recent Development
11.20 Takeda
11.20.1 Takeda Company Detail
11.20.2 Takeda Business Overview
11.20.3 Takeda Brand Drugs Introduction
11.20.4 Takeda Revenue in Brand Drugs Business (2019-2024)
11.20.5 Takeda Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
